New treatment for chronic kidney disease approved in the EU
The European Commission (EC) has approved Jardiance® (empagliflozin) for the treatment of adults with chronic kidney disease
Search
World Veterinary Day aspects veterinary profession
• World Veterinary Day 2024 celebrates the essential work of veterinarians, yet new data show only 49% of veterinary professionals believe their profession is appreciated.
Phase 3 studies survodutide obesity and overweight
Phase 3 studies to investigate survodutide for people living with obesity and overweight, with and without diabetes, cardiovascular disease and chronic kidney disease
Stem cell therapy for tendon and ligament injuries in horses
A tendon or ligament injury can be devastating for horse owners, riders and trainers. Our new stem cell product improves the quality of healing.
LastMile increases access to veterinary care in Africa
Boehringer Ingelheim’s LastMile initiative reaches over 40,000 smallholder farmers in Sub-Saharan Africa increasing access to veterinary medicine
SENVELGO Best New Product Companion Animals award
SENVELGO won the 2023 Animal Health Best New Product for Companion Animals award
Development Biotechnology sustainable cell culture
Boehringer Ingelheim refines its bioprocess technology operations in Animal Health with greater focus on environmental sustainability to reduce footprint
Boehringer Ingelheim announces appointments Board of Managing Directors
Boehringer Ingelheim announces appointments Board of Managing Directors
Investment of 65 million euro in avian vaccines in France
Boehringer Ingelheim is set to invest almost €65 million in a high-tech building at its Lyon Portes-des-Alpes site in Saint-Priest, France (Rhône), to meet the growing demand worldwide for avian vaccines
PREVEXXION® RN: Marek’s disease vaccine available in EU UK
Boehringer Ingelheim is pleased to announce the launch of the next generation of Marek’s disease vaccines is now available in the EU.
Boehringer Ingelheim Social Engagements
Boehringer Ingelheim Social Engagements Contributes to company commitment to impact 50 million people in vulnerable communities by 2030 through supporting social entrepreneurs and innovative solutions
Questions and Answers
Answers to common questions from both patients and health care professionals regarding Compassionate Use of experimental medications.
Monoclonal antibodies Boehringer Ingelheim and Invetx
Boehringer Ingelheim and Invetx announce collaboration to discover, develop and commercialize novel veterinary monoclonal antibody biotherapeutics
Women in STEM 2022
Meet three of Boehringer Ingelheim's female scientists and learn why and how women are making a difference in STEM.
Investment social engagements in Cowtribe veterinary startup
Last-mile veterinary delivery social start-up Cowtribe first investment of Boehringer Ingelheim Social Engagements
Veronika Kohlbrenner
Veronika Kohlbrenner, Patient Safety Physician in Therapeutic Area Inflammation, tells us how she is able to work across different levels of the drug development process.
Vaccine bluetongue virus serotype 3 sheep cattle
BULTAVO 3™ is a new vaccine that protects cattle and sheep against bluetongue virus serotype 3 (BTV-3). BULTAVO 3™ is the first BTV-3 vaccine that prevents clinical signs and mortality.
Breakthrough in Artificial Intelligence ChatGPT
Is ChatGPT the AI revolution we were waiting for or only media hype? Experts from Boehringer Ingelheim take a close look.
Valerie Nock
My career challengeFunctional Areas at Boehringer Ingelheim
FreVAX smartphone application piglet vaccination
New FreVAX™ smartphone application brings piglet vaccination to another level
New positive data in Phase III type 2 diabetes trial
DINAMO Phase III trial demonstrated empagliflozin significantly reduced blood sugar levels in children and adolescents with type 2 diabetes
Phase 1 start for novel triple agonist obesity treatment
Boehringer and Gubra announce Phase 1 study of BI 3034701, a long-acting, next generation, first-in-class triple agonist peptide for obesity treatment
emperor-reduced-chmp-positive-opinion
CHMP issues positive opinion for the treatment of adults with heart failure with reduced ejection fraction
Aservo EquiHaler wins Pharmapack Award 2021
Boehringer Ingelheim’s Aservo® EquiHaler® is recognized in the 2021 Pharmapack Awards
meat consumption market trends growth sustainability
In this article, we’re taking a look at global developments while highlighting one of the most important meat markets of the future: the Asian continent.